Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endocrine cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    170 result(s) found for: Endocrine cells. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2020-001898-78 Sponsor Protocol Number: CABOTEM Start Date*: 2020-11-12
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of combination between Cabozantinib and Temozolomide in Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib...
    Medical condition: Patient with Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib or PRRT.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028196 Multiple endocrine neoplasias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015523-91 Sponsor Protocol Number: ENM-EA-011 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universiätsklinik Graz, Abteilung für Endokrinologie und Nuklearmedizin
    Full Title: Placebo controlled study on effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters
    Medical condition: healthy volunteers. The intended indication for the investigated product is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension), metabolic (e.g...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007792-24 Sponsor Protocol Number: 1.1 Start Date*: 2009-03-13
    Sponsor Name:Medical University of Graz, Department of Internal Medicine, Div. Endocrinology and Nuclear Medicine
    Full Title: Effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters
    Medical condition: Healthy volunteers. The intended indication for the product under development is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension) metabolic ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000879-24 Sponsor Protocol Number: IJB-BC-NEORHEA-2016 Start Date*: 2017-03-23
    Sponsor Name:Institut Jules Bordet
    Full Title: Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002832-24 Sponsor Protocol Number: CZOL446GDE21 Start Date*: 2005-07-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine...
    Medical condition: Hormonreceptor positive breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012189-30 Sponsor Protocol Number: BC1-09 Start Date*: 2009-10-30
    Sponsor Name:Algeta ASA
    Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy
    Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018901-12 Sponsor Protocol Number: ADPP-002ENM-DA-017 Start Date*: 2010-10-20
    Sponsor Name:Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism [...]
    1. Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism
    2.
    Full Title: Placebo controlled study on effects of vitamin D supplementation in type 1 diabetic subjects on immunological, endocrine and metabolic parameters: Step 2 of the Austrian Diabetes Prevention Program...
    Medical condition: To evaluate whether vitamin D supplementation in type 1 diabetic subjects significantly alters the proportion of regulatory T-cells of all circulating CD4 positive T-cells.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005326-29 Sponsor Protocol Number: IBCSG_41-13 Start Date*: 2013-11-11
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine r...
    Medical condition: Premenopausal patients with histologically confirmed locally advanced breast cancer and with primary tumor of ER+/PgR+ and HER2 negative or not amplified.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002249-22 Sponsor Protocol Number: D-V Start Date*: 2015-07-15
    Sponsor Name:Universitätsklinikum Ulm (AöR)
    Full Title: DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pert...
    Medical condition: Patients with HER2-positive and hormone-receptor positive metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003897-24 Sponsor Protocol Number: ICRCTSU/2019/10068 Start Date*: 2020-07-06
    Sponsor Name:The Institute of Cancer Research
    Full Title: PreOperative Endocrine Therapy for Individualised Care with Abemaciclib
    Medical condition: Non-metastatic operable invasive ER+ HER2- breast cancer in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001629-23 Sponsor Protocol Number: GIM10-CONSENT Start Date*: 2013-07-19
    Sponsor Name:IRCCS AOU SAN MARTINO- IST
    Full Title: A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrine-responsive...
    Medical condition: Breast cancer is the most common form of cancer among women in North America, Europe and Latin America. Beacause nearly 80% of breast cancers are endocrine-responsive tumors, the majority of patien...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000764-42 Sponsor Protocol Number: UC-0140/1606 Start Date*: 2016-10-12
    Sponsor Name:UNICANCER
    Full Title: A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration Afte...
    Medical condition: Patients with ER+ and HER2- primary non-metastatic breast cancer who are eligible to neoadjuvant endocrine therapy.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000074-51 Sponsor Protocol Number: GBG 39 Start Date*: 2005-05-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer
    Medical condition: patients with HER2 negative metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004022-36 Sponsor Protocol Number: CCR5316 Start Date*: 2022-01-07
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus fulvestrant versus standard endocrine therapy in patients with ER...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004536-28 Sponsor Protocol Number: 1 Start Date*: 2021-11-15
    Sponsor Name:Uppsala University, Department of Women's and Children´s Health
    Full Title: Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longi...
    Medical condition: Most troublesome vulvovaginal atrophy symptom
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003435-13 Sponsor Protocol Number: MARLENE Start Date*: 2021-05-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer
    Medical condition: HER2 negative hormone receptors positive metastatic breast cancer progressed after CDK 4/6 inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007310 Carcinoma breast stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004497-15 Sponsor Protocol Number: ERGO Start Date*: 2016-12-12
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in C...
    Medical condition: Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004498-34 Sponsor Protocol Number: SUM Start Date*: 2016-12-12
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodie...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000129-28 Sponsor Protocol Number: GO42784 Start Date*: 2021-08-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WIT...
    Medical condition: Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) SK (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003434-18 Sponsor Protocol Number: IBCSG 32-05/ BIG 1-05 Start Date*: 2006-05-04
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III Trials Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suit...
    Medical condition: Older women (66 years of age or older) with histologically proven, resected breast cancer. The disease must be classified as endocrine nonresponsive and patients must not be candidates for endocrin...
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) SI (Completed) IT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 09:42:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA